Clinical and Microbiological Outcomes of Serious Infections with Multidrug-Resistant Gram-Negative Organisms Treated with Tigecycline

Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase-and extended-spectrum β -lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration v...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2008-02, Vol.46 (4), p.567-570
Main Authors: Anthony, Kara B., Fishman, Neil O., Linkin, Darren R., Gasink, Leanne B., Edelstein, Paul H., Lautenbach, Ebbing
Format: Article
Language:English
Subjects:
Acinetobacter baumannii
Acinetobacter baumannii - isolation & purification
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteremia
Bacteria
beta-Lactamases - biosynthesis
Biological and medical sciences
Brief Reports
Carbapenems
Dosage
Drug resistance
Drug Resistance, Multiple, Bacterial
Drug therapy
Enterobacteriaceae
Enterobacteriaceae - isolation & purification
Female
Gram-Negative Bacteria - drug effects
Gram-Negative Bacterial Infections - drug therapy
Gram-Negative Bacterial Infections - microbiology
Health outcomes
Humans
Infections
Infectious diseases
Klebsiella pneumoniae
Klebsiella pneumoniae - isolation & purification
Male
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Minocycline - analogs & derivatives
Minocycline - therapeutic use
Pharmacology. Drug treatments
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase-and extended-spectrum β -lactamase-producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available.
ISSN:1058-4838
1537-6591
DOI:10.1086/526775